Kangtai Biological Products (300601.SZ)

Executive Summary

Kangtai Biological Products (BioKangtai) is a leading Chinese vaccine developer with a diversified portfolio spanning hepatitis B, pneumococcal, varicella, polio, and COVID-19 vaccines. The company leverages multiple platforms including live attenuated, inactivated, recombinant protein, polysaccharide conjugate, and viral vector technologies. Its commercial-stage products generate stable revenue, while the pipeline focuses on next-generation vaccines to address unmet needs in infectious diseases. Key recent developments include the launch of its 13-valent pneumococcal conjugate vaccine (PCV13) and ongoing trials for a recombinant COVID-19 vaccine. With strong manufacturing capabilities and distribution in China, Kangtai is well-positioned to capture growth from expanding immunization programs and potential export opportunities. However, competition from domestic and international players and regulatory risks remain key challenges. The company's financial health and R&D execution will be critical to sustaining momentum.

Upcoming Catalysts (preview)

• Q3 2026Approval of 13-valent pneumococcal conjugate vaccine (PCV13) for infants80% success
• Q4 2026Phase 3 data readout for recombinant COVID-19 vaccine (beta variant)70% success
• Q1 2027Expansion of varicella vaccine market share through WHO prequalification60% success